Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

fect of P-gp Inducers & Inhibitors on Dabigatran Exposure
The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS
In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in higher rates of major GI bleeds and any GI bleeds compared to warfarin. In patients >75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated
In the pivotal trial, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA (0.7 per 100 patient-years for 150 mg dose) than in those who received warfarin (0.6).

Click

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... the medical device industry gathers at Sales and Marketing Excellence 2010 ... device companies a solution to promote and sell in this highly regulated ... Maureen Shaffer ... "Sales-Friendly Compliant Content Communication: How to Score Wins for Sales, Marketing, and ...
... Georgia , May 20, 2010 , ... - Critical Care Pharmacology Course Promotes Patient ... ... than 1,300 healthcare organizations,has partnered with the American Association of Critical-Care Nurses (AACN) ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 2Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 4Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 5Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 6Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 7
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... HAVEN, Conn., May 29 ... today announced that an analysis of clinical data of ... myeloid leukemia (AML) would be presented in a poster ... Annual Meeting in Orlando, Florida.The poster (Abstract #7050) entitled ...
... Minimally Invasive Spine Surgery Provides Better Diagnosis and Treatment ... Kenneth L. Reed, M.D. performed the first revolutionary ... to treat acute and chronic back pain ... physicians are the only doctors performing the procedure in ...
... available for incontinence nowadays, an effective and easy solution ... incontinence. The main roadblock to that solution might just ... his condition. Dr. Peter Muench of Delaware Urologic Associates ... advises patients that full disclosure is the best policy ...
... Scottish Widows paid over £28m in critical illness cover claims between November ... due to non-disclosure, The three main reasons for claims - cancer, heart ... ... Scottish Widows, one of the most trusted brands in life insurance ...
... in a Series of Community Discussions on Improving Access ... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... roundtables as part of their Year of Affordable Healthcare ... at the YMCA San Francisco, aimed at raising awareness ...
... balloon also floated by President Clinton in 1993 to pay ... comes to finding a way to finance government-run health care, ... balloon echoing that of President Bill Clinton in 1993.The Obama ... spokesman for Obama Budget Director Peter Orszag, who was quoted ...
Cached Medicine News:Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 3Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 3Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 4Health News:Scottish Widows Releases Critical Illness Cover Claims Figures 2Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:ATR: Obama's VAT Trial Balloon Dusts Off Bill Clinton's 1993 Playbook 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: